Improved Quality of Life , Clinicians showing examples of Trial Patients Responding to Treatment positively..
Patients would drop out of the trial had SNT 5505 delivered a detrimental effect on their Health ,
Reduction in Spleen size ....
We believe we have a competitive Profile and a Valuable Treatment....
Positive Phase II Data delivering confidence to clinicians and Trial Patients ....
Patients getting better from longer exposure ....
Update in March 2025...
Time for an Afternoon Latte
NZT
- Forums
- ASX - By Stock
- Ann: Presentation: Phase 2 study of SNT-5505 in myelofibrosis
SNT
syntara limited
Add to My Watchlist
1.72%
!
5.7¢

Improved Quality of Life , Clinicians showing examples of Trial...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
5.7¢ |
Change
-0.001(1.72%) |
Mkt cap ! $92.62M |
Open | High | Low | Value | Volume |
5.8¢ | 5.9¢ | 5.6¢ | $174.0K | 3.073M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.7¢ | 483082 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 83031 | 0.055 |
2 | 110908 | 0.054 |
4 | 394430 | 0.053 |
3 | 172230 | 0.052 |
3 | 372100 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.057 | 483082 | 1 |
0.060 | 240854 | 3 |
0.061 | 150000 | 1 |
0.062 | 125000 | 3 |
0.063 | 568340 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
SNT (ASX) Chart |
The Watchlist
CDE
CODEIFAI LIMITED
John Houston / Martin Ross, Executive Chairman / COO
John Houston / Martin Ross
Executive Chairman / COO
Previous Video
Next Video
SPONSORED BY The Market Online